Early data show cancer progression associated with increased risk of death in patients with COVID-19
Research suggests treatment with combination of hydroxychloroquine and azithromycin also strongly associated with greater risk of death
In patients with cancer and COVID-19, cancer that is progressing was independently associated with an increased risk of death, according to an analysis of 928 patients.
COVID-19 treatment with both hydroxychloroquine and azithromycin was also strongly associated with increased risk of death, according to data from the COVID-19 and Cancer Consortium (CCC19) registry. The registry contains data from patients who have tested positive for COVID-19 and around 40% of patients in the registry also have active cancer.
The data was presented as part of the virtual scientific programme of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
Study at a Glance
|Focus||30-day all-cause mortality|
|Population||525 patients with cancer diagnosed with COVID-19|
|Findings||Cancer progression and treatment with hydroxychloroquine and azithromycin were associated with a 5.2-fold and 2.89-fold greater risk of death at 30 days compared with patients in remission/no evidence of disease|
|Significance||The findings could lead to better understanding of the relationship between cancer and COVID-19 to improve care for these patients|